Market Cap 3.51B
Revenue (ttm) 75.13M
Net Income (ttm) -146.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -194.88%
Debt to Equity Ratio 0.00
Volume 2,410,700
Avg Vol 7,325,620
Day's Range N/A - N/A
Shares Out 306.61M
Stochastic %K 14%
Beta 1.32
Analysts Strong Sell
Price Target $17.12

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a researc...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 559 9005
Address:
150 W 4th Avenue, Vancouver, Canada
Stocktradesmoon
Stocktradesmoon Sep. 10 at 2:16 AM
$ABCL Part 1) I've now listened to the Cantor conference fireside chat again... and to be honest, I'm now more bullish than ever. So many things I could talk about....admittance into FDA’s Model-Informed Drug Development program, Phase 2/3 trial design for breast cancer then prostate cancer, preclinical data for 688 and 386 that is equivalent to ABCL635, etc. etc. BUT... did you know that we already have another molecule in IND-enabling studies? Yes, you read that right... it's a follow-on.
0 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 10 at 2:15 AM
$ABCL Part 2) Hansen's exact words: “In fact, for ABCL635, we have already brought into IND enabling studies a follow-on that is engineered for even longer half-life because we see that as white space. This is a giant opportunity, we want to leave no white space for anyone.” The results for ABCL635 are so good that we are now in the process of making ABCL635 with a longer half-life.. What if you only need one injection every 3 or 6 months? Well, we are in the process of doing exactly that. He didn't mentioned what the half-life would be but he's thinking several steps ahead. He's actively discouraging any future competition by doing it himself.
0 · Reply
tradersunion353
tradersunion353 Sep. 10 at 12:55 AM
$ABCL a dip to 9.50s and then to the moon 9.50s to 15-20 dollars by end of the year 🎉🎉
0 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 9 at 11:33 PM
$ABCL GET in NOW! We’re going to $15+ THIS Week! ABCL CEO CARL on the Call today said that PHASE 2 RESULTS were so IMPRESSIVE that PATIENTS Were “CURED”! “One of the really UNPRECEDENTED and, I’d say, very exciting parts of the data was that in 37% of patients after a 1 dose of ABCL635, they went from a baseline of around 10 events per day to ZERO! So for a subset of a significant subset of patients, like more than a third, a 1 dose was essentially curative “CURED”at 4weeks. And on the severity side, I think that number was like 25%. And thats important because severity if you have even a minor event, which you kind of are aware of it, it doesn’t stop you, it doesn’t really interfere with your events, that gets a score on severity. So we had about 24% W/ ZERO severity score, which means there were NO EVENTS! So NOT A SINGLE INCIDENT. So from someone that was really STRUGGLING with this to essentially ITS GONE, thats SOMETHING that you RARELY, RARELY see in drug development” 🤯🤯 🤯
1 · Reply
JennyRowes
JennyRowes Sep. 9 at 10:48 PM
$ABCL on call Carl indicated a launch around 2030. rember, they started development this year. and, in case it needs to be pointed put, 5 years from phase 1 to launch is awesomely fast
0 · Reply
traderjoe41
traderjoe41 Sep. 9 at 10:25 PM
$NAUT Starting to move...$IBRX, $ABCL, $HIMS,
1 · Reply
Rastafari
Rastafari Sep. 9 at 9:55 PM
$ABCL What a great call today! If you listen carefully, Carl’s tone was incredibly upbeat, and for me, three things really stood out: 1. ABCL635 is a billion-dollar asset. Carl made it clear that he believes this drug is potentially superior to anything else currently on the market. 2. They are talking to potential partners to accelerate the drug to market. If the commercial terms make sense, they are open to bringing in a partner to help accelerate development and commercialization. 3. The biggest asset AbCellera has may actually be the platform itself. The ability to rapidly uncover and develop new drug candidates is incredibly valuable. ABCL635 could be just one example of what this platform can produce. Know what you own, people. There will be trading ranges, volatility and fluctuations in the share price—that’s part of the game. But one thing I don’t believe is going to happen: this baby isn’t going to be trading at $11 at year-end. Stay patient. Know what you own.
2 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 9 at 9:30 PM
$ABCL "We have two programs, ABCL688 and 386, that are on track to be in the clinic next year. If you had asked me two months ago to grade them, I would have said that they are on par with ABCL635. ABCL635 is my favorite right now, but you never know" - Hansen
0 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 9 at 9:28 PM
$ABCL "Two months ago, no one was paying attention to ABCL635. Now it is all they pay attention to...The platform and the drugs that it is going to make from here are going to be the most valuable thing about the company moving forward" - Carl Hansen
0 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 9 at 9:17 PM
$ABCL GET in NOW! We’re going to $15+ THIS Week! ABCL CEO CARL on the Call today said that PHASE 2 RESULTS were so IMPRESSIVE that PATIENTS Were “CURED”! “One of the really UNPRECEDENTED and, I’d say, very exciting parts of the data was that in 37% of patients after a 1 dose of ABCL635, they went from a baseline of around 10 events per day to ZERO! So for a subset of a significant subset of patients, like more than a third, a 1 dose was essentially curative “CURED”at 4weeks. And on the severity side, I think that number was like 25%. And thats important because severity if you have even a minor event, which you kind of are aware of it, it doesn’t stop you, it doesn’t really interfere with your events, that gets a score on severity. So we had about 24% W/ ZERO severity score, which means there were NO EVENTS! So NOT A SINGLE INCIDENT. So from someone that was really STRUGGLING with this to essentially ITS GONE, thats SOMETHING that you RARELY, RARELY see in drug development” 🤯🤯 🤯
1 · Reply
Latest News on ABCL
AbCellera rises 17.0%

2026-08-25T16:06:05.000Z - 15 days ago

AbCellera rises 17.0%


AbCellera rises 10.7%

2026-08-25T14:06:36.000Z - 15 days ago

AbCellera rises 10.7%


AbCellera announces $200M common stock, warrants offering

2026-08-11T20:05:47.000Z - 4 weeks ago

AbCellera announces $200M common stock, warrants offering


AbCellera price target raised to $30 from $12 at Truist

2026-08-11T13:35:37.000Z - 4 weeks ago

AbCellera price target raised to $30 from $12 at Truist


AbCellera Biologics Slides: Corporate presentation

Aug 10, 2026, 8:00 AM EDT - 4 weeks ago

AbCellera Biologics Slides: Corporate presentation


AbCellera Biologics Transcript: Study result

Aug 10, 2026, 7:30 AM EDT - 4 weeks ago

AbCellera Biologics Transcript: Study result


AbCellera Biologics Press release: Study result

Aug 10, 2026, 7:30 AM EDT - 4 weeks ago

AbCellera Biologics Press release: Study result


AbCellera Biologics Slides: Study result

Aug 10, 2026, 7:30 AM EDT - 4 weeks ago

AbCellera Biologics Slides: Study result


AbCellera price target raised to $9 from $8 at Stifel

2026-08-06T12:20:50.000Z - 4 weeks ago

AbCellera price target raised to $9 from $8 at Stifel


AbCellera Biologics Earnings Call Transcript: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 5 weeks ago

AbCellera Biologics Earnings Call Transcript: Q2 2026


AbCellera Biologics Slides: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 5 weeks ago

AbCellera Biologics Slides: Q2 2026


AbCellera Biologics Earnings release: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 5 weeks ago

AbCellera Biologics Earnings release: Q2 2026


AbCellera Biologics Quarterly report: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 5 weeks ago

AbCellera Biologics Quarterly report: Q2 2026


AbCellera Reports Q2 2026 Business Results

Aug 5, 2026, 4:05 PM EDT - 5 weeks ago

AbCellera Reports Q2 2026 Business Results


AbCellera upgraded to Buy from Hold at Benchmark

2026-07-07T10:35:14.000Z - 2 months ago

AbCellera upgraded to Buy from Hold at Benchmark

JAZZ


AbCellera apponts Lynn Seely to board of directors

2026-07-06T13:15:29.000Z - 2 months ago

AbCellera apponts Lynn Seely to board of directors

LYEL


AbCellera Appoints Dr. Lynn Seely to its Board of Directors

Jul 6, 2026, 9:00 AM EDT - 2 months ago

AbCellera Appoints Dr. Lynn Seely to its Board of Directors


AbCellera Appoints Dr. Victor Sandor to its Board of Directors

Jun 5, 2026, 9:00 AM EDT - 3 months ago

AbCellera Appoints Dr. Victor Sandor to its Board of Directors


AbCellera Biologics Earnings Call Transcript: Q1 2026

May 11, 2026, 5:00 PM EDT - 4 months ago

AbCellera Biologics Earnings Call Transcript: Q1 2026


AbCellera Biologics Earnings release: Q1 2026

May 11, 2026, 5:00 PM EDT - 4 months ago

AbCellera Biologics Earnings release: Q1 2026


AbCellera Biologics Quarterly report: Q1 2026

May 11, 2026, 5:00 PM EDT - 4 months ago

AbCellera Biologics Quarterly report: Q1 2026


AbCellera Biologics Slides: Q1 2026

May 11, 2026, 5:00 PM EDT - 4 months ago

AbCellera Biologics Slides: Q1 2026


AbCellera Biologics Slides: Corporate presentation

May 1, 2026, 8:00 AM EDT - 4 months ago

AbCellera Biologics Slides: Corporate presentation


AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 4 months ago

AbCellera Biologics Proxy statement: Proxy filing


AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 4 months ago

AbCellera Biologics Proxy statement: Proxy filing


AbCellera Biologics Earnings Call Transcript: Q4 2025

Feb 24, 2026, 5:00 PM EST - 6 months ago

AbCellera Biologics Earnings Call Transcript: Q4 2025


AbCellera Biologics Annual report: Q4 2025

Feb 24, 2026, 5:00 PM EST - 6 months ago

AbCellera Biologics Annual report: Q4 2025


AbCellera Biologics Earnings release: Q4 2025

Feb 24, 2026, 5:00 PM EST - 6 months ago

AbCellera Biologics Earnings release: Q4 2025


AbCellera Biologics Slides: Q4 2025

Feb 24, 2026, 5:00 PM EST - 6 months ago

AbCellera Biologics Slides: Q4 2025


AbCellera Reports Full Year 2025 Business Results

Feb 24, 2026, 4:05 PM EST - 6 months ago

AbCellera Reports Full Year 2025 Business Results


AbCellera Biologics Slides: Corporate presentation

Jan 14, 2026, 7:00 AM EST - 7 months ago

AbCellera Biologics Slides: Corporate presentation


AbCellera Biologics Transcript: Stifel 2025 Healthcare Conference

Nov 13, 2025, 8:00 AM EST - 10 months ago

AbCellera Biologics Transcript: Stifel 2025 Healthcare Conference


AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 10, 2025, 9:00 AM EST - 10 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors


AbCellera Biologics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 5:00 PM EST - 10 months ago

AbCellera Biologics Earnings Call Transcript: Q3 2025


AbCellera Biologics Quarterly report: Q3 2025

Nov 6, 2025, 5:00 PM EST - 10 months ago

AbCellera Biologics Quarterly report: Q3 2025


AbCellera Biologics Earnings release: Q3 2025

Nov 6, 2025, 5:00 PM EST - 10 months ago

AbCellera Biologics Earnings release: Q3 2025


AbCellera Biologics Slides: Q3 2025

Nov 6, 2025, 5:00 PM EST - 10 months ago

AbCellera Biologics Slides: Q3 2025


AbCellera Reports Q3 2025 Business Results

Nov 6, 2025, 4:05 PM EST - 10 months ago

AbCellera Reports Q3 2025 Business Results


AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Sep 10, 2025, 9:07 AM EDT - 12 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer


AbCellera Biologics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q2 2025


AbCellera Biologics Quarterly report: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q2 2025


AbCellera Biologics Earnings release: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q2 2025


AbCellera Biologics Slides: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q2 2025


AbCellera Biologics Slides: Corporate Presentation

Aug 1, 2025, 7:00 AM EDT - 1 year ago

AbCellera Biologics Slides: Corporate Presentation


AbCellera Biologics Earnings Call Transcript: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q1 2025


AbCellera Biologics Earnings release: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q1 2025


AbCellera Biologics Quarterly report: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q1 2025


AbCellera Biologics Slides: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q1 2025


AbCellera Reports Q1 2025 Business Results

May 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2025 Business Results


AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing


AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing


AbCellera Biologics Earnings Call Transcript: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q4 2024


AbCellera Biologics Earnings release: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q4 2024


AbCellera Biologics Annual report: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Annual report: Q4 2024


AbCellera Biologics Slides: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q4 2024


AbCellera Reports Full Year 2024 Business Results

Feb 27, 2025, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2024 Business Results


AbCellera Biologics Slides: FY 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Slides: FY 2025


AbCellera Biologics Earnings Call Transcript: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q3 2024


AbCellera Biologics Quarterly report: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Quarterly report: Q3 2024


AbCellera Biologics Earnings release: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q3 2024


AbCellera Biologics Slides: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q3 2024


AbCellera Reports Q3 2024 Business Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results


Stocktradesmoon
Stocktradesmoon Sep. 10 at 2:16 AM
$ABCL Part 1) I've now listened to the Cantor conference fireside chat again... and to be honest, I'm now more bullish than ever. So many things I could talk about....admittance into FDA’s Model-Informed Drug Development program, Phase 2/3 trial design for breast cancer then prostate cancer, preclinical data for 688 and 386 that is equivalent to ABCL635, etc. etc. BUT... did you know that we already have another molecule in IND-enabling studies? Yes, you read that right... it's a follow-on.
0 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 10 at 2:15 AM
$ABCL Part 2) Hansen's exact words: “In fact, for ABCL635, we have already brought into IND enabling studies a follow-on that is engineered for even longer half-life because we see that as white space. This is a giant opportunity, we want to leave no white space for anyone.” The results for ABCL635 are so good that we are now in the process of making ABCL635 with a longer half-life.. What if you only need one injection every 3 or 6 months? Well, we are in the process of doing exactly that. He didn't mentioned what the half-life would be but he's thinking several steps ahead. He's actively discouraging any future competition by doing it himself.
0 · Reply
tradersunion353
tradersunion353 Sep. 10 at 12:55 AM
$ABCL a dip to 9.50s and then to the moon 9.50s to 15-20 dollars by end of the year 🎉🎉
0 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 9 at 11:33 PM
$ABCL GET in NOW! We’re going to $15+ THIS Week! ABCL CEO CARL on the Call today said that PHASE 2 RESULTS were so IMPRESSIVE that PATIENTS Were “CURED”! “One of the really UNPRECEDENTED and, I’d say, very exciting parts of the data was that in 37% of patients after a 1 dose of ABCL635, they went from a baseline of around 10 events per day to ZERO! So for a subset of a significant subset of patients, like more than a third, a 1 dose was essentially curative “CURED”at 4weeks. And on the severity side, I think that number was like 25%. And thats important because severity if you have even a minor event, which you kind of are aware of it, it doesn’t stop you, it doesn’t really interfere with your events, that gets a score on severity. So we had about 24% W/ ZERO severity score, which means there were NO EVENTS! So NOT A SINGLE INCIDENT. So from someone that was really STRUGGLING with this to essentially ITS GONE, thats SOMETHING that you RARELY, RARELY see in drug development” 🤯🤯 🤯
1 · Reply
JennyRowes
JennyRowes Sep. 9 at 10:48 PM
$ABCL on call Carl indicated a launch around 2030. rember, they started development this year. and, in case it needs to be pointed put, 5 years from phase 1 to launch is awesomely fast
0 · Reply
traderjoe41
traderjoe41 Sep. 9 at 10:25 PM
$NAUT Starting to move...$IBRX, $ABCL, $HIMS,
1 · Reply
Rastafari
Rastafari Sep. 9 at 9:55 PM
$ABCL What a great call today! If you listen carefully, Carl’s tone was incredibly upbeat, and for me, three things really stood out: 1. ABCL635 is a billion-dollar asset. Carl made it clear that he believes this drug is potentially superior to anything else currently on the market. 2. They are talking to potential partners to accelerate the drug to market. If the commercial terms make sense, they are open to bringing in a partner to help accelerate development and commercialization. 3. The biggest asset AbCellera has may actually be the platform itself. The ability to rapidly uncover and develop new drug candidates is incredibly valuable. ABCL635 could be just one example of what this platform can produce. Know what you own, people. There will be trading ranges, volatility and fluctuations in the share price—that’s part of the game. But one thing I don’t believe is going to happen: this baby isn’t going to be trading at $11 at year-end. Stay patient. Know what you own.
2 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 9 at 9:30 PM
$ABCL "We have two programs, ABCL688 and 386, that are on track to be in the clinic next year. If you had asked me two months ago to grade them, I would have said that they are on par with ABCL635. ABCL635 is my favorite right now, but you never know" - Hansen
0 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 9 at 9:28 PM
$ABCL "Two months ago, no one was paying attention to ABCL635. Now it is all they pay attention to...The platform and the drugs that it is going to make from here are going to be the most valuable thing about the company moving forward" - Carl Hansen
0 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 9 at 9:17 PM
$ABCL GET in NOW! We’re going to $15+ THIS Week! ABCL CEO CARL on the Call today said that PHASE 2 RESULTS were so IMPRESSIVE that PATIENTS Were “CURED”! “One of the really UNPRECEDENTED and, I’d say, very exciting parts of the data was that in 37% of patients after a 1 dose of ABCL635, they went from a baseline of around 10 events per day to ZERO! So for a subset of a significant subset of patients, like more than a third, a 1 dose was essentially curative “CURED”at 4weeks. And on the severity side, I think that number was like 25%. And thats important because severity if you have even a minor event, which you kind of are aware of it, it doesn’t stop you, it doesn’t really interfere with your events, that gets a score on severity. So we had about 24% W/ ZERO severity score, which means there were NO EVENTS! So NOT A SINGLE INCIDENT. So from someone that was really STRUGGLING with this to essentially ITS GONE, thats SOMETHING that you RARELY, RARELY see in drug development” 🤯🤯 🤯
1 · Reply
tradersunion353
tradersunion353 Sep. 9 at 7:55 PM
$ABCL buy order set at 9.80 for 12244 shares easy 50% from here
1 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 9 at 7:43 PM
$ABCL “One of the really UNPRECEDENTED and, I'd say, very exciting parts of the data was that in 37% of patients after a single dose of ABCL635, they went from a baseline of around 10 events per day to ZERO! So for a subset of a significant subset of patients, like more than a third, a Single dose was essentially curative at 4weeks. And on the severity side, I think that number was like 25%. And that's important because severity if you have even a minor event, which you kind of are aware of it, it doesn't stop you, it doesn't really interfere with your events, that gets a score on severity. So we had about 24% W/ ZERO severity score, which means there were NO EVENTS! So NOT A SINGLE INCIDENT. So from someone that was really STRUGGLING with this to essentially ITS GONE, thats SOMETHING that you RARELY, RARELY see in drug development” 🤯🤯 🤯
1 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 9 at 7:42 PM
$ABCL $ABCL A MUST LISTEN!!🎧 CONFERENCE CALL AT CANTOR CONFERENCE With CEO CARL 🤯 . The PHASE 2 RESULTS SO IMPRESSIVE he USED the WORD “CURED” the Patients! The BEST LIVE WEBCAST I have seen in a Long time! SUPER IMPRESSIVE!! When People START listening to this CALL TODAY and TONIGHT we are going to start moving to $15’sss. So MUCH GREAT NEWS and NUGGETS DROPPED ON THIS CALL!
0 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 9 at 7:22 PM
$ABCL 🤯 🤯 Incredible Podcast Cantor Conference With ABCL CEO CARL! PHASE 2 RESULTS SO IMPRESSIVE HE ACTUALLY USED THE WORD “CURE” on some patients ! 🤯 “One of the really UNPRECEDENTED and, I'd say, very exciting parts of the data was that in 37% of patients after a single dose of ABCL635, they went from a baseline of around 10 events per day to ZERO! So for a subset of a significant subset of patients, like more than a third, a Single dose was essentially curative at 4weeks. And on the severity side, I think that number was like 25%. And that's important because severity if you have even a minor event, which you kind of are aware of it, it doesn't stop you, it doesn't really interfere with your events, that gets a score on severity. So we had about 24% W/ ZERO severity score, which means there were NO EVENTS! So NOT A SINGLE INCIDENT. So from someone that was really STRUGGLING with this to essentially ITS GONE, that's SOMETHING that you RARELY, RARELY see in drug development” 🤯
0 · Reply
loadbeforeexplode
loadbeforeexplode Sep. 9 at 7:16 PM
0 · Reply
MagicRon_
MagicRon_ Sep. 9 at 7:11 PM
$ABCL Chin up BullTards - I'm sure they will drop that PR soon, and this will moon! "The tutes are loading"!!🚀😆
0 · Reply
tranq19
tranq19 Sep. 9 at 6:40 PM
$ABCL carl "entertaining" offers for 635 already..."we capitalized to take it alone, but if the right partner, right deal comes along that could be a game changer for 635." they raised capital to put them in a better bargaining position, he talked about 2030 commercial launch, but my bet is they get an offer they cant turn down long before. He also said, company and 635 value only increases as they progress
0 · Reply
tradersunion353
tradersunion353 Sep. 9 at 6:22 PM
$ABCL buy at 9.30 - 9.50 range sell at 15 by year end easy peasy 50% rinse and repeat
3 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 9 at 6:04 PM
$ABCL @Rastafari A lot of Great things HAPPENING with $ABCL! It is Shaping to be a Powerouse and Megalith of a Company! $13-15’sss this Week!!!
0 · Reply
Rastafari
Rastafari Sep. 9 at 5:55 PM
$ABCL by 2.30 we will turn green!
1 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 9 at 4:06 PM
$ABCL @UncleTomFlorida @DavinB @Rastafari @Stocktradesmoon @ayman1245 @Buying_Low_Selling_High @abcluv @JoshKatz96 @odoji @tunderhi @Bobadhu @MrHurts @Mike11111111 @Polarbear1 @BruceyMatt Link to LIVE webcast: https://t.co/UcSsLVygqO
2 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 9 at 3:52 PM
$ABCL @snowPOW @Instwr @Agentg @JiZzM0pper216 @XxZeeMoneyxX @twalker79 @8008track @Quadruple_Double @Biker68 @DeMampCamp @Ckkung71 @Ivanectus @hichemben @Samb2344 @deputy1420 Link to LIVE webcast: https://t.co/UcSsLVygqO
1 · Reply